search
Back to results

Stress Neuroadaptation in Tobacco Dependence

Primary Purpose

Nicotine Dependence

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
nicotine
placebo
Sponsored by
University of Wisconsin, Madison
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Nicotine Dependence

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • cigarette use over 10 cigarettes/day for over two years;
  • smoking within the first 30 minutes of waking up
  • expired air carbon monoxide (CO) level >6 ppm
  • self-reported motivation to quit smoking
  • and an agreement to respond to ecological momentary assessment prompts (via SMS) throughout the day for three weeks.

Exclusion Criteria:

  • Health screening are performed by questionnaire and reviewed by study staff (RA or Research Specialist) to ensure that smokers can safely use the nicotine patch and lozenge. Specifically, smokers will be excluded for FDA contraindications for nicotine replacement therapy (i.e., no uncontrolled hypertension, recent myocardial infarction, diabetes, heart disease, asthma, stomach ulcers).
  • All women of child-bearing potential will be required to agree to use an approved method of birth control to prevent pregnancy during the course of the study.
  • All participants will report no medical or psychiatric condition that would contraindicate exposure to electric shock.
  • Participants with uncorrected auditory or visual problems will be excluded.

Additional Data Exclusions

  1. As part of the NPU stressor task, smokers are asked to indicate if the participant "can be shocked in the next 5 seconds" at various points during the task. Responses to these questions are used to verify that the participant understands the cue-shock contingencies. Smokers who answer < 10 out of 14 questions correctly the NPU stressor task during the experimental session will be excluded from all analyses and replaced.
  2. Smokers with 20% of cue trials identified as artifact in the NPU task will be excluded from all analyses and replaced.
  3. The analysis will NOT exclude smokers who are startle non-responders given that the use of these surrogate endpoints in practice would likely need to include these individuals to avoid unnecessary data loss.
  4. Smokers who do not report a complete abstinence between quit date/time and final laboratory visit (which occurs 12-36 hours later) will be considered to not have quit and will be excluded from all analyses and replaced.
  5. Smokers for whom the investigators cannot definitively quantify an outcome with respect to continuous abstinence will be excluded from all analyses and replaced. Any report of smoking during the two-week cessation period (reported either during the 4x daily web surveys or the laboratory visit at 2 weeks) is sufficient to code the smoker to have lapsed (i.e., not continuously abstinent), even if the participants do not complete the full two weeks of web surveys and/or the 2-week laboratory visit. However, the status of smokers who report no smoking during the cessation attempt but have both a high level of missing data from the web surveys (> 25% of reports) and no two-week laboratory visit report will be deemed uncertain. These smokers will be excluded and replaced.
  6. The investigators will conduct case analyses to identify participants who are model outliers with Bonferroni-corrected studentized residuals p < 0.05. These model outliers will be excluded but NOT replaced (because the participants are not identified until after data collection has been completed).

Sites / Locations

  • University of Wisconsin

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Active Comparator

Active Comparator

Arm Label

Active Deprived

Active Non-deprived

Placebo Deprived

Placebo Non-deprived

Arm Description

21 mg nicotine patches and 2 mg nicotine lozenges + First NPU task takes place 24 hours after start of quit attempt

21 mg nicotine patches and 2 mg nicotine lozenges + First NPU task takes place during normal smoking prior to quit attempt

Placebo patches and placebo lozenges + First NPU task takes place 24 hours after start of quit attempt

Placebo patches and placebo lozenges + First NPU task takes place during normal smoking prior to quit attempt

Outcomes

Primary Outcome Measures

Overall Stressor Reactivity
The average of unpredictable startle potentiation and predictable startle potentiation during the first administration of the NPU stressor task.
Relative Unpredictable Stressor Reactivity
Unpredictable startle potentiation minus predictable startle potentiation during the first administration of the NPU stressor task
Change in Overall Stressor Reactivity
A difference score of overall stressor reactivity during the second administration of the NPU stressor task relative to the first NPU stressor task
Change in Relative Unpredictable Stressor Reactivity
A difference score of relative unpredictable stressor reactivity during the second administration of the NPU stressor task relative to the first NPU stressor task

Secondary Outcome Measures

Full Information

First Posted
August 23, 2017
Last Updated
April 1, 2019
Sponsor
University of Wisconsin, Madison
search

1. Study Identification

Unique Protocol Identification Number
NCT03262233
Brief Title
Stress Neuroadaptation in Tobacco Dependence
Official Title
Clinical Relevance of Stress Neuroadaptation in Tobacco Dependence
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
April 1, 2015 (Actual)
Primary Completion Date
February 20, 2018 (Actual)
Study Completion Date
February 20, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Wisconsin, Madison

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of the current study is to evaluate the validity of the No Shock, Predictable Shock, Unpredictable Shock (NPU) stressor task for use as a surrogate endpoint to predict short-term clinical outcomes among smokers during a smoking cessation attempt.
Detailed Description
Smokers recruited for this study are randomly assigned at a screening session to complete the NPU stressor task pre-quit or post-quit (i.e., nicotine deprived or non-deprived). Participants are also randomized to receive either placebo or active combination nicotine replacement therapy (NRT; patches and lozenges) for a two week smoking cessation period. The NPU stressor task measures stressor reactivity to predictable and unpredictable stressors (i.e., electric shock). Startle potentiation during predictable and unpredictable stressors (relative to no-shock) provides the primary measures of stressor reactivity in this task. Predictable and unpredictable startle potentiation are used to calculate overall stressor reactivity and selective unpredictable stressor reactivity. Further detail on these reactivity measures is provided in the Independent Variables section. Detail on the quantification of startle potentiation is provided at the end of this registration. Smokers provide three weeks (1 week pre-quit, 2 weeks post-quit) of brief 4x daily, real-time web-survey reports of recent cigarette use, NRT use, and other measures not relevant to this study's purpose on the participants' smartphones. At two weeks post-quit, smokers are scheduled for a laboratory visit where participants provide an additional report via staff interview of any smoking during the two-week smoking cessation period. The stressor reactivity measures from the NPU task will be tested as predictors of clinical outcome (i.e., continuous abstinence during the two-week cessation period) to evaluate the validity of each as surrogate endpoints for use in research on stress mechanisms in smoking relapse. Deprivation status at the time of the NPU stressor task will be examined as a moderator of the effect of stressor reactivity to determine if the surrogate endpoints predict clinical outcome generally or only as deprivation increases.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nicotine Dependence

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
226 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Active Deprived
Arm Type
Experimental
Arm Description
21 mg nicotine patches and 2 mg nicotine lozenges + First NPU task takes place 24 hours after start of quit attempt
Arm Title
Active Non-deprived
Arm Type
Experimental
Arm Description
21 mg nicotine patches and 2 mg nicotine lozenges + First NPU task takes place during normal smoking prior to quit attempt
Arm Title
Placebo Deprived
Arm Type
Active Comparator
Arm Description
Placebo patches and placebo lozenges + First NPU task takes place 24 hours after start of quit attempt
Arm Title
Placebo Non-deprived
Arm Type
Active Comparator
Arm Description
Placebo patches and placebo lozenges + First NPU task takes place during normal smoking prior to quit attempt
Intervention Type
Combination Product
Intervention Name(s)
nicotine
Intervention Type
Other
Intervention Name(s)
placebo
Primary Outcome Measure Information:
Title
Overall Stressor Reactivity
Description
The average of unpredictable startle potentiation and predictable startle potentiation during the first administration of the NPU stressor task.
Time Frame
up to 24 hours after start of cessation attempt (deprived groups); during normal smoking prior to quit attempt, ie. Baseline (non-deprived groups)
Title
Relative Unpredictable Stressor Reactivity
Description
Unpredictable startle potentiation minus predictable startle potentiation during the first administration of the NPU stressor task
Time Frame
up to 24 hours post cessation attempt (deprived groups); during normal smoking prior to quit attempt, ie. Baseline (non-deprived groups)
Title
Change in Overall Stressor Reactivity
Description
A difference score of overall stressor reactivity during the second administration of the NPU stressor task relative to the first NPU stressor task
Time Frame
baseline and up to 14 days post cessation attempt (non-deprived groups); baseline and up to 24 hours post quit attempt (deprived groups)
Title
Change in Relative Unpredictable Stressor Reactivity
Description
A difference score of relative unpredictable stressor reactivity during the second administration of the NPU stressor task relative to the first NPU stressor task
Time Frame
baseline and up to 14 days post cessation attempt (non-deprived groups); baseline and up to 24 hours post quit attempt (deprived groups)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: cigarette use over 10 cigarettes/day for over two years; smoking within the first 30 minutes of waking up expired air carbon monoxide (CO) level >6 ppm self-reported motivation to quit smoking and an agreement to respond to ecological momentary assessment prompts (via SMS) throughout the day for three weeks. Exclusion Criteria: Health screening are performed by questionnaire and reviewed by study staff (RA or Research Specialist) to ensure that smokers can safely use the nicotine patch and lozenge. Specifically, smokers will be excluded for FDA contraindications for nicotine replacement therapy (i.e., no uncontrolled hypertension, recent myocardial infarction, diabetes, heart disease, asthma, stomach ulcers). All women of child-bearing potential will be required to agree to use an approved method of birth control to prevent pregnancy during the course of the study. All participants will report no medical or psychiatric condition that would contraindicate exposure to electric shock. Participants with uncorrected auditory or visual problems will be excluded. Additional Data Exclusions As part of the NPU stressor task, smokers are asked to indicate if the participant "can be shocked in the next 5 seconds" at various points during the task. Responses to these questions are used to verify that the participant understands the cue-shock contingencies. Smokers who answer < 10 out of 14 questions correctly the NPU stressor task during the experimental session will be excluded from all analyses and replaced. Smokers with 20% of cue trials identified as artifact in the NPU task will be excluded from all analyses and replaced. The analysis will NOT exclude smokers who are startle non-responders given that the use of these surrogate endpoints in practice would likely need to include these individuals to avoid unnecessary data loss. Smokers who do not report a complete abstinence between quit date/time and final laboratory visit (which occurs 12-36 hours later) will be considered to not have quit and will be excluded from all analyses and replaced. Smokers for whom the investigators cannot definitively quantify an outcome with respect to continuous abstinence will be excluded from all analyses and replaced. Any report of smoking during the two-week cessation period (reported either during the 4x daily web surveys or the laboratory visit at 2 weeks) is sufficient to code the smoker to have lapsed (i.e., not continuously abstinent), even if the participants do not complete the full two weeks of web surveys and/or the 2-week laboratory visit. However, the status of smokers who report no smoking during the cessation attempt but have both a high level of missing data from the web surveys (> 25% of reports) and no two-week laboratory visit report will be deemed uncertain. These smokers will be excluded and replaced. The investigators will conduct case analyses to identify participants who are model outliers with Bonferroni-corrected studentized residuals p < 0.05. These model outliers will be excluded but NOT replaced (because the participants are not identified until after data collection has been completed).
Facility Information:
Facility Name
University of Wisconsin
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53706
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
IPD will be shared on the data repository at Open Science Foundation
IPD Sharing Time Frame
Data will be available on submission of first manuscript based on study
IPD Sharing Access Criteria
Data are completely open
IPD Sharing URL
https://osf.io/dz9yu/

Learn more about this trial

Stress Neuroadaptation in Tobacco Dependence

We'll reach out to this number within 24 hrs